Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.
2.

Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy.

Stegman LD, Rehemtulla A, Hamstra DA, Rice DJ, Jonas SJ, Stout KL, Chenevert TL, Ross BD.

Gene Ther. 2000 Jun;7(12):1005-10.

3.

Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response.

Moffat BA, Chenevert TL, Lawrence TS, Meyer CR, Johnson TD, Dong Q, Tsien C, Mukherji S, Quint DJ, Gebarski SS, Robertson PL, Junck LR, Rehemtulla A, Ross BD.

Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5524-9. Epub 2005 Apr 1.

4.

Combined radiation and enzyme/prodrug treatment for head and neck cancer in an orthotopic animal model.

Hamstra DA, Rice DJ, Pu A, Oyedijo D, Ross BD, Rehemtulla A.

Radiat Res. 1999 Nov;152(5):499-507.

PMID:
10521927
5.

Diffusion-weighted magnetic resonance imaging early after chemoradiotherapy to monitor treatment response in head-and-neck squamous cell carcinoma.

Vandecaveye V, Dirix P, De Keyzer F, Op de Beeck K, Vander Poorten V, Hauben E, Lambrecht M, Nuyts S, Hermans R.

Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1098-107. doi: 10.1016/j.ijrobp.2011.02.044. Epub 2011 Apr 20.

PMID:
21514067
6.

Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.

Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS, Rehemtulla A, Ross BD.

J Natl Cancer Inst. 2000 Dec 20;92(24):2029-36.

7.

Fractional change in apparent diffusion coefficient as an imaging biomarker for predicting treatment response in head and neck cancer treated with chemoradiotherapy.

Matoba M, Tuji H, Shimode Y, Toyoda I, Kuginuki Y, Miwa K, Tonami H.

AJNR Am J Neuroradiol. 2014 Feb;35(2):379-85. doi: 10.3174/ajnr.A3706. Epub 2013 Sep 12.

8.

A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy.

Galbán CJ, Mukherji SK, Chenevert TL, Meyer CR, Hamstra DA, Bland PH, Johnson TD, Moffat BA, Rehemtulla A, Eisbruch A, Ross BD.

Transl Oncol. 2009 Aug 18;2(3):184-90.

9.

Predictive and prognostic role of functional imaging of head and neck squamous cell carcinomas.

Quon H, Brizel DM.

Semin Radiat Oncol. 2012 Jul;22(3):220-32. doi: 10.1016/j.semradonc.2012.03.007. Review.

PMID:
22687947
10.

Early prediction of response to radiotherapy and androgen-deprivation therapy in prostate cancer by repeated functional MRI: a preclinical study.

Røe K, Kakar M, Seierstad T, Ree AH, Olsen DR.

Radiat Oncol. 2011 Jun 8;6:65. doi: 10.1186/1748-717X-6-65.

11.

Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.

Luedke E, Jaime-Ramirez AC, Bhave N, Roda J, Choudhary MM, Kumar B, Teknos TN, Carson WE 3rd.

Surgery. 2012 Sep;152(3):431-40. doi: 10.1016/j.surg.2012.05.035. Epub 2012 Jul 6.

12.

Imaging biomarker dynamics in an intracranial murine glioma study of radiation and antiangiogenic therapy.

Chung C, Jalali S, Foltz W, Burrell K, Wildgoose P, Lindsay P, Graves C, Camphausen K, Milosevic M, Jaffray D, Zadeh G, Ménard C.

Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):805-12. doi: 10.1016/j.ijrobp.2012.07.005. Epub 2012 Aug 26.

PMID:
22929856
13.

INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.

[No authors listed]

Drugs R D. 2007;8(3):176-87. Review.

PMID:
17472413
14.

[Role and responsibility of multimodal imaging in head and neck cancer].

Gõdény M.

Magy Onkol. 2013 Sep;57(3):182-202. doi: MagyOnkol.2013.57.3.182. Epub 2013 Sep 20. Review. Hungarian.

15.

A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck.

Varveris H, Mazonakis M, Vlachaki M, Kachris S, Lyraraki E, Zoras O, Maris T, Froudarakis M, Velegrakis J, Perysinakis C, Damilakis J, Samonis G.

Oncol Rep. 2003 Jan-Feb;10(1):185-95.

PMID:
12469168
16.

Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer.

Harry VN, Semple SI, Gilbert FJ, Parkin DE.

Gynecol Oncol. 2008 Nov;111(2):213-20. doi: 10.1016/j.ygyno.2008.07.048. Epub 2008 Sep 6.

PMID:
18774597
17.

Pretreatment diffusion-weighted and dynamic contrast-enhanced MRI for prediction of local treatment response in squamous cell carcinomas of the head and neck.

Chawla S, Kim S, Dougherty L, Wang S, Loevner LA, Quon H, Poptani H.

AJR Am J Roentgenol. 2013 Jan;200(1):35-43. doi: 10.2214/AJR.12.9432.

18.
19.

Diffusion-weighted EPI- and HASTE-MRI and 18F-FDG-PET-CT early during chemoradiotherapy in advanced head and neck cancer.

Schouten CS, de Bree R, van der Putten L, Noij DP, Hoekstra OS, Comans EF, Witte BI, Doornaert PA, Leemans CR, Castelijns JA.

Quant Imaging Med Surg. 2014 Aug;4(4):239-50. doi: 10.3978/j.issn.2223-4292.2014.07.15.

20.

Dose painting in radiotherapy for head and neck squamous cell carcinoma: value of repeated functional imaging with (18)F-FDG PET, (18)F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI.

Dirix P, Vandecaveye V, De Keyzer F, Stroobants S, Hermans R, Nuyts S.

J Nucl Med. 2009 Jul;50(7):1020-7. doi: 10.2967/jnumed.109.062638. Epub 2009 Jun 12.

Items per page

Supplemental Content

Write to the Help Desk